Document Detail

Enalapril reduces QTc dispersion in mild congestive heart failure secondary to coronary artery disease.
MedLine Citation:
PMID:  9036753     Owner:  NLM     Status:  MEDLINE    
This study was designed to investigate the possible mechanisms whereby enalapril improves cardiac function and mortality in chronic heart failure. We explored potential mechanisms by following 41 patients with early heart failure over the course of 1 year. These patients were randomized in a prospective triple-blind manner to receive either enalapril or placebo. Over the 1 year, repeated measurements were obtained of echocardiographic parameters, glomerular filtration rate, renal blood flow, hematocrit, plasma neurohormones, and QTc dispersion. Echocardiographic parameters improved with enalapril but deteriorated with placebo (cardiac output 4.6 +/- 1.6 to 3.7 +/- 1.5 L/min with placebo, and 4.5 +/- 1.3 to 5.8 +/- 2.0 L/min with enalapril; p <0.01). In contrast, there were no significant changes in renal blood flow (518 +/- 185 to 509 +/- 180 ml/min/1.73 m2 with placebo, and 541 +/- 142 to 504 +/- 162 ml/min/1.73 m2 with enalapril). Glomerular filtration rate changed from 79 +/- 20 to 78 +/- 19 ml/min/1.73 m2 with placebo, and from 85 +/- 21 to 73 +/- 27 ml/min/1.73 m2 with enalapril (p = 0.051). Enalapril reduced hematocrit (0.414 +/- 0.041 to 0.377 +/- 0.040%) significantly more than placebo (0.420 +/- 0.029 to 0.411 +/- 0.023 l/l; p <0.01). In addition, enalapril produced a marked reduction in QTc dispersion (93 +/- 36 to 88 +/- 28 ms with placebo and 93 +/- 35 to 60 +/- 22 ms with enalapril; p <0.05). Thus, enalapril significantly reduced hematocrit and reduced QTc dispersion in early heart failure. Both of these effects, but especially the latter, could be an important mechanism for the reduced mortality seen with angiotensin-converting enzyme inhibitors in heart failure. In contrast, renal hemodynamics did not parallel either the placebo-induced deterioration in cardiac function or the enalapril-induced improvements in cardiac function.
C S Barr; A A Naas; M Fenwick; A D Struthers
Related Documents :
21993993 - Coronary sinus ostial atresia with persistent left superior vena cava demonstrated on c...
11686913 - A comparison of the qt and qtc dispersion among patients with sustained ventricular tac...
2962483 - Relation between infarct size and left ventricular performance assessed in patients wit...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The American journal of cardiology     Volume:  79     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  1997 Feb 
Date Detail:
Created Date:  1997-02-27     Completed Date:  1997-02-27     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  328-33     Citation Subset:  AIM; IM    
Department of Clinical Pharmacology, Ninewells Hospital and Medical School, Dundee, United Kingdom.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiotensin-Converting Enzyme Inhibitors / pharmacology*,  therapeutic use
Coronary Disease / complications*,  physiopathology
Double-Blind Method
Drug Therapy, Combination
Enalapril / pharmacology*,  therapeutic use
Heart Failure / drug therapy*,  etiology,  physiopathology*
Hemodynamics / drug effects*
Middle Aged
Neurosecretory Systems / drug effects
Prospective Studies
Treatment Outcome
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 75847-73-3/Enalapril
Comment In:
Am J Cardiol. 1997 Dec 15;80(12):1643   [PMID:  9416960 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Right and left ventricular hemodynamic performance during sustained ventricular tachycardia.
Next Document:  Prediction of surgical strategy in mitral valve regurgitation based on echocardiography. Interuniver...